← Leaderboards
Donald B Kohn
University Of Southern California
$24,055,774
Attributed
$28,536,892
Total exposure
43
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$47,519,205 · 44
FDA$880,618 · 1
By mechanism
P01$22,767,545 · 8
U01$9,953,087 · 2
R01$5,838,766 · 5
T32$2,718,011 · 1
P60$2,225,461 · 1
U54$1,683,615 · 2
Top collaborators
- David A Williams5 shared
- Jose A. Cancelas3 shared
- Lilith Reeves2 shared
- Jennifer Maxwell Puck1 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Robert C Seeger$12,536,093
- Robertson Parkman$2,369,452
- Kenneth I. Weinberg$11,172,423
- Laurence H Kedes$5,584,649
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$80,540,126
- David T Scadden · Massachusetts General Hospital$40,987,034
- David A Williams · Indiana Univ-Purdue Univ At Indianapolis$36,503,708
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
Research focus
Hematopoietic Stem CellsGene TherapyClinical ResearchTransfection /Expression VectorGene ExpressionClinical TrialsHuman SubjectVectorGenesSourceGenetic TransductionGene TransferResearch PersonnelUnited States National Institutes Of HealthLaboratory MouseAids TherapyLentivirus VectorComplementary DnaCellsLentivirusCd34 MoleculeHiv InfectionsBone Marrow TransplantationInfant
Grant awards (122)
Training in Developmental Hematology$165,456
T32 · FY2022 · HL · contact PI
Training in Developmental Hematology$329,347
T32 · FY2021 · HL · contact PI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,371,788
U01 · FY2020 · TR
Training in Developmental Hematology$248,884
T32 · FY2020 · HL · contact PI
Primary Immune Deficiency Treatment Consortium$1,604,571
U54 · FY2019 · AI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,357,953
U01 · FY2019 · TR
Training in Developmental Hematology$308,490
T32 · FY2019 · HL · contact PI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,340,745
U01 · FY2018 · TR
Training in Developmental Hematology$297,379
T32 · FY2018 · HL · contact PI
Analysis of B-Cell Tolerance in Wiskott-Aldrich Syndrome Following Stem Cell Transplantation$79,044
U54 · FY2018 · AI · contact PI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,408,459
U01 · FY2017 · TR
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,242,732
U01 · FY2016 · TR
EFS-ADA Lentiviral Vector Transduction of Bone Marrow CD34+ Cells for ADA-SCID$592,671
U01 · FY2016 · AI · contact PI
Training in Developmental Hematology$200,846
T32 · FY2016 · HL · contact PI
EFS-ADA Lentiviral Vector Transduction of Bone Marrow CD34+ Cells for ADA-SCID$611,999
U01 · FY2015 · AI · contact PI
Training in Developmental Hematology$234,931
T32 · FY2015 · HL · contact PI
EFS-ADA Lentiviral Vector Transduction of Bone Marrow CD34+ Cells for ADA-SCID$686,892
U01 · FY2014 · AI · contact PI
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of Melanoma$299,973
P01 · FY2014 · CA · contact PI
Training in Developmental Hematology$216,787
T32 · FY2014 · HL · contact PI
Gene Therapy Using Hematopoietic Stem Cells$1,774,220
P01 · FY2013 · HL · contact PI
EFS-ADA Lentiviral Vector Transduction of Bone Marrow CD34+ Cells for ADA-SCID$640,723
U01 · FY2013 · AI · contact PI
Training in Developmental Hematology$270,913
T32 · FY2013 · HL · contact PI
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of Melanoma$267,685
P01 · FY2013 · CA · contact PI
Gene Therapy Using Hematopoietic Stem Cells$1,863,676
P01 · FY2012 · HL · contact PI
EFS-ADA Lentiviral Vector Transduction of Bone Marrow CD34+ Cells for ADA-SCID$699,125
U01 · FY2012 · AI · contact PI
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of Melanoma$285,613
P01 · FY2012 · CA · contact PI
Training in Developmental Hematology$245,488
T32 · FY2012 · HL · contact PI
Gene Therapy Using Hematopoietic Stem Cells$1,863,676
P01 · FY2011 · HL · contact PI
In Vivo ADA Gene Delivery for the Treatment of SCID$454,321
R01 · FY2011 · AI · contact PI
MND-ADA Transduced CD34 Cells for ADA-SCID$423,718
R01 · FY2011 · FD · contact PI
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of Melanoma$286,084
P01 · FY2011 · CA · contact PI
Training in Developmental Hematology$199,490
T32 · FY2011 · HL · contact PI
IN VIVO ADA GENE DELIVERY FOR THE TREATMENT OF SCID$75,629
P51 · FY2011 · RR · contact PI
Gene Therapy Using Hematopoietic Stem Cells$1,868,463
P01 · FY2010 · HL · contact PI
In Vivo ADA Gene Delivery for the Treatment of SCID$474,430
R01 · FY2010 · AI · contact PI
Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of Melanoma$294,932
P01 · FY2010 · CA · contact PI
IN VIVO ADA GENE DELIVERY FOR THE TREATMENT OF SCID$114,105
P51 · FY2010 · RR · contact PI
Gene Therapy Using Hematopoietic Stem Cells$1,881,963
P01 · FY2009 · HL · contact PI
MND-ADA Transduced CD34 Cells for ADA-SCID$456,900
R01 · FY2009 · FD · contact PI
In Vivo ADA Gene Delivery for the Treatment of SCID$455,581
R01 · FY2009 · AI · contact PI
CLINICAL TRIAL: TRANSDUCTION OF CD34+ CELLS FROM THE UMBILICAL CORD BLOOD OF INF$156,530
M01 · FY2009 · RR · contact PI
LENTIVIRAL VECTOR FOR GENE TRANSFER TO HEMATOPOIETIC STEM CELLS$142,265
P51 · FY2009 · RR · contact PI
IN VIVO ADA GENE DELIVERY FOR THE TREATMENT OF SCID$106,671
P51 · FY2009 · RR · contact PI
CLINICAL TRIAL: LONG-TERM FOLLOW-UP FOR STUDIES OF GENE TRANSFER (HIV AND OTHERS$18,916
M01 · FY2009 · RR · contact PI
In Vivo ADA Gene Delivery for the Treatment of SCID$483,204
R01 · FY2008 · AI · contact PI
LENTIVIRAL VECTOR FOR GENE TRANSFER TO HEMATOPOIETIC STEM CELLS$108,444
P51 · FY2008 · RR · contact PI
Conference--American Society of Gene Therapy$10,000
R13 · FY2008 · HL · contact PI
LONG-TERM FOLLOW-UP FOR STUDIES OF GENE TRANSFER (HIV AND OTHERS)$3,317
M01 · FY2008 · RR · contact PI
GENE THERAPY USING HEMATOPOIETIC STEM CELLS$1,833,466
P01 · FY2007 · HL · contact PI
In Vivo ADA Gene Delivery for the Treatment of SCID$478,870
R01 · FY2007 · AI · contact PI
Gene Therapy for ADA-Deficient SCID$313,191
P01 · FY2007 · HL · contact PI
TRANSDUCTION OF CD34+ CELLS FROM THE UMBILICAL CORD BLOOD OF INFANTS OR THE B$123,076
M01 · FY2007 · RR · contact PI
LENTIVIRAL VECTOR FOR GENE TRANSFER TO HEMATOPOIETIC STEM CELLS$106,637
P51 · FY2007 · RR · contact PI
LONG-TERM FOLLOW-UP FOR STUDIES OF GENE TRANSFER (HIV AND OTHERS)$20,631
M01 · FY2007 · RR · contact PI
Conference--American Society of Gene Therapy$20,000
R13 · FY2007 · HL · contact PI
GENE THERAPY USING HEMATOPOIETIC STEM CELLS$1,835,836
P01 · FY2006 · HL · contact PI
Gene Therapy for ADA-Deficient SCID$310,214
P01 · FY2006 · HL · contact PI
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$156,653
P51 · FY2006 · RR · contact PI
Clinical Trial Planning Grant: Lentiviral Vector for HIV-1$114,225
R34 · FY2006 · AI · contact PI
TRANSDUCTION OF CD34+ CELLS FROM THE UMBILICAL CORD BLOOD OF INFANTS OR THE B$58,789
M01 · FY2006 · RR · contact PI
Conference--American Society of Gene Therapy$10,000
R13 · FY2006 · HL · contact PI
LONG-TERM FOLLOW-UP FOR STUDIES OF GENE TRANSFER$5,445
M01 · FY2006 · RR · contact PI
GENE THERAPY USING HEMATOPOIETIC STEM CELLS$1,827,927
P01 · FY2005 · HL
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$462,766
R01 · FY2005 · AI
Gene Therapy for ADA-Deficient SCID$303,071
P01 · FY2005 · HL
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$207,141
P51 · FY2005 · RR
Conference--American Society of Gene Therapy$10,000
R13 · FY2005 · HL
LONG-TERM FOLLOW-UP FOR STUDIES OF GENE TRANSFER$9,297
M01 · FY2005 · RR
TREATMENT OF SEVERE COMBINED IMMUNE DEFICIENCY DISEASE DUE TO ADA DEFICIENCY$1,032
M01 · FY2005 · RR
MND-ADA Transduced CD34 Cells for ADA-SCID$0
R01 · FY2005 · FD
MND-ADA Transduced CD34 Cells for ADA-SCID$0
R01 · FY2005 · FD
GENE THERAPY USING HEMATOPOIETIC STEM CELLS$1,777,260
P01 · FY2004 · HL
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$451,060
R01 · FY2004 · AI
Gene Therapy for ADA-Deficient SCID$296,060
P01 · FY2004 · HL
Core A-- Administrative Core$69,601
P01 · FY2004 · HL
Conference--American Society of Gene Therapy$10,000
R13 · FY2004 · HL
Transfer of RevM10 and FX Genes into Bone Marrow$6,450
M01 · FY2004 · RR
TRANSDUCTION OF CD34+ CELLS FROM THE BONE MARROW OF HIV-1 INFECTED CHILDREN$6,450
M01 · FY2004 · RR
TREATMENT OF SEVERE COMBINED IMMUNE DEFICIENCY DISEASE$6,419
M01 · FY2004 · RR
GENE THERAPY USING HEMATOPOIETIC STEM CELLS$1,731,873
P01 · FY2003 · HL
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$444,459
R01 · FY2003 · AI
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$181,302
P51 · FY2003 · RR
GENE EXPRESSION IN BETA-CELLS BY LENTIVIRAL VECTORS$149,600
R21 · FY2003 · DK
IN VITRO AND IN VIVO MODELS OF HUMAN ERYTHROPOIESIS$498,057
P60 · FY2002 · HL
IN VITRO AND IN VIVO MODELS OF HUMAN ERYTHROPOIESIS$498,057
P60 · FY2002 · HL
IN VITRO AND IN VIVO MODELS OF HUMAN ERYTHROPOIESIS$498,057
P60 · FY2002 · HL
LENTIVIRAL VECTOR TRANSFER TO HEMATOPOIETIC STEM CELLS$442,808
R01 · FY2002 · AI
CORE--GENE TRANSDUCTION AND GENE THERAPY$185,520
P50 · FY2002 · HL
MECHANISMS OF GENE SILENCING$184,121
P01 · FY2002 · CA
CORE--VECTOR DEVELOPMENT$184,121
P01 · FY2002 · CA
GENE EXPRESSION IN BETA-CELLS BY LENTIVIRAL VECTORS$149,600
R21 · FY2002 · DK
TRANSDUCTION OF CD34 PERIPHERAL BLOOD PROGENITAL CELL FROM HIV INFECTED PERSONS$0
M01 · FY2002 · RR
TRANSDUCTION OF CD34+ CELLS FROM THE BONE MARROW OF HIV-1 INFECTED CHILDREN$0
M01 · FY2002 · RR
RETROVIRUS AND LENTIVIRUS FOR STEM CELL TRANSDUCTION$0
P01 · FY2002 · AI
IN VITRO AND IN VIVO MODELS OF HUMAN ERYTHROPOIESIS$498,057
P60 · FY2001 · HL
GENE THERAPY FOR HURLERS DISEASE$294,112
R01 · FY2001 · DK
CORE--GENE TRANSDUCTION AND GENE THERAPY$185,520
P50 · FY2001 · HL
CORE--GENE TRANSDUCTION AND GENE THERAPY$185,520
P50 · FY2001 · HL
CORE--VECTOR DEVELOPMENT$184,121
P01 · FY2001 · CA
MECHANISMS OF GENE SILENCING$184,121
P01 · FY2001 · CA
TRANSDUCTION OF CD34 PERIPHERAL BLOOD PROGENITAL CELL FROM HIV INFECTED PERSONS$155,764
M01 · FY2001 · RR
TRANSDUCTION OF CD34+ CELLS FROM THE BONE MARROW OF HIV-1 INFECTED CHILDREN$155,764
M01 · FY2001 · RR
TRANSDUCTION OF CD34+ CELLS FROM THE BONE MARROW OF HIV-1 INFECTED CHILDREN$0
M01 · FY2001 · RR
RETROVIRUS AND LENTIVIRUS FOR STEM CELL TRANSDUCTION$0
P01 · FY2001 · AI
RETROVIRUS AND LENTIVIRUS FOR STEM CELL TRANSDUCTION$0
P01 · FY2001 · AI
RETROVIRUS AND LENTIVIRUS FOR STEM CELL TRANSDUCTION$0
P01 · FY2001 · AI
HEMATOPOIETIC STEM CELLS FOR GENE THERAPY WITH REV M10$0
P01 · FY2001 · AI
HEMATOPOIETIC STEM CELLS FOR GENE THERAPY WITH REV M10$0
P01 · FY2001 · AI
TRANSDUCTION OF CD34 PERIPHERAL BLOOD PROGENITAL CELL FROM HIV INFECTED PERSONS$0
M01 · FY2001 · RR
GENE THERAPY FOR HURLERS DISEASE$285,636
R01 · FY2000 · DK
RETROVIRUS AND LENTIVIRUS FOR STEM CELL TRANSDUCTION$237,837
P01 · FY2000 · AI
IN VITRO AND IN VIVO MODELS OF HUMAN ERYTHROPOIESIS$233,233
P60 · FY2000 · HL
MODIFIED RETROVIRAL VECTORS FOR HSC GENE THERAPY$230,901
R01 · FY2000 · DK
HEMATOPOIETIC STEM CELLS FOR GENE THERAPY WITH REV M10$220,099
P01 · FY2000 · AI
HEMATOPOIETIC STEM CELLS FOR GENE THERAPY WITH REV M10$220,099
P01 · FY2000 · AI
CORE--GENE TRANSDUCTION AND GENE THERAPY$185,520
P50 · FY2000 · HL
MECHANISMS OF GENE SILENCING$184,121
P01 · FY2000 · CA
CORE--VECTOR DEVELOPMENT$184,121
P01 · FY2000 · CA
TRANSDUCTION OF CD34+ CELLS FROM THE BONE MARROW OF HIV-1 INFECTED CHILDREN$35,553
M01 · FY2000 · RR
TRANSDUCTION OF CD34 PERIPHERAL BLOOD PROGENITAL CELL FROM HIV INFECTED PERSONS$35,553
M01 · FY2000 · RR
TRANSDUCTION OF CD34+ CELLS FROM THE BONE MARROW OF HIV-1 INFECTED CHILDREN$0
M01 · FY2000 · RR
TRANSDUCTION OF CD34 PERIPHERAL BLOOD PROGENITAL CELL FROM HIV INFECTED PERSONS$0
M01 · FY2000 · RR